Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBIT Margin (2018 - 2025)

BioNexus Gene Lab's EBIT Margin history spans 8 years, with the latest figure at 213.5% for Q4 2025.

  • Quarterly results put EBIT Margin at 213.5% for Q4 2025, down 19701.0% from a year ago — trailing twelve months through Dec 2025 was 39.93% (down 2339.0% YoY), and the annual figure for FY2025 was 39.93%, down 2339.0%.
  • EBIT Margin for Q4 2025 was 213.5% at BioNexus Gene Lab, down from 27.62% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 13.13% in Q2 2024 to a low of 213.5% in Q4 2025.
  • The 5-year median for EBIT Margin is 3.82% (2022), against an average of 21.76%.
  • The sharpest move saw EBIT Margin surged 4816bps in 2024, then plummeted -19701bps in 2025.
  • Year by year, EBIT Margin stood at 6.2% in 2021, then crashed by -170bps to 4.32% in 2022, then surged by 362bps to 11.34% in 2023, then tumbled by -245bps to 16.49% in 2024, then plummeted by -1195bps to 213.5% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 213.5%, 27.62%, and 27.05% for Q4 2025, Q3 2025, and Q2 2025 respectively.